2198-6576

Rheumatology and Therapy

Springer-Verlag

View prefix report (10.1007)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 862 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact862 DOIs
2

Attach ORCID iDs across 345 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact345 DOIs
3

Add license metadata to 60 records

License metadata tells indexers and readers how each article may be reused.

Low impact60 DOIs

DOIs for this ISSN

Showing the top 5 of 862 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Osteosarcoma Overview (10.1007/s40744-016-0050-2)
Abstract ORCID License
192.53 368
2 Review of Osteosarcoma and Current Management (10.1007/s40744-016-0046-y)
Abstract ORCID License
187.78 318
3 Juvenile Idiopathic Arthritis: Diagnosis and Treatment (10.1007/s40744-016-0040-4)
Abstract ORCID License
169.68 182
4 Psoriatic Arthritis and Burden of Disease: Patient Perspecti… (10.1007/s40744-016-0029-z)
Abstract ORCID License
168.96 178
5 Rituximab for Rheumatoid Arthritis (10.1007/s40744-015-0016-9)
Abstract ORCID License
146.20 88
6 Hypersensitivity to Orthopedic Implants: A Review of the Lit… (10.1007/s40744-017-0062-6)
Abstract ORCID License
143.93 82
7 First Real-World Insights into Belimumab Use and Outcomes in… (10.1007/s40744-016-0047-x)
Abstract ORCID License
141.49 76
8 Secukinumab: A New Treatment Option for Psoriatic Arthritis (10.1007/s40744-016-0031-5)
Abstract ORCID License
126.76 48
9 An Update on Treatment and Management of Pediatric Systemic… (10.1007/s40744-016-0044-0)
Abstract ORCID License
124.71 45
10 Ustekinumab in the Treatment of Psoriasis and Psoriatic Arth… (10.1007/s40744-015-0010-2)
Abstract ORCID License
123.99 44
11 bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative R… (10.1007/s40744-017-0055-5)
Abstract ORCID License
123.99 44
12 Depression Risk in Patients with Rheumatoid Arthritis in the… (10.1007/s40744-017-0058-2)
Abstract ORCID License
122.51 42
13 Incidence of Gastrointestinal Perforations in Patients with… (10.1007/s40744-016-0037-z)
Abstract ORCID License
120.15 39
14 Pharmacokinetics and Bioequivalence Study of Hydroxychloroqu… (10.1007/s40744-015-0012-0)
Abstract ORCID License
116.72 35
15 A Blinded, Randomized, Placebo-Controlled Study to Investiga… (10.1007/s40744-017-0088-9)
Abstract ORCID License
113.89 32
16 Systemic Lupus Erythematosus (SLE) Therapy: The Old and the… (10.1007/s40744-020-00212-9)
Abstract ORCID
113.36 184
17 Concomitant Use of Statins in Tocilizumab-Treated Patients w… (10.1007/s40744-016-0049-8)
Abstract ORCID License
112.89 31
18 Rheumatoid Arthritis: The Impact of Mental Health on Disease… (10.1007/s40744-020-00217-4)
Abstract ORCID
111.01 165
19 Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatmen… (10.1007/s40744-014-0005-4)
Abstract ORCID License
110.78 29
20 Patient Perceptions and Preferences of Two Etanercept Autoin… (10.1007/s40744-016-0048-9)
Abstract ORCID License
109.68 28
21 Emerging Therapies for Rheumatoid Arthritis (10.1007/s40744-016-0032-4)
Abstract ORCID License
108.54 27
22 Role of Human Leukocyte Antigens (HLA) in Autoimmune Disease… (10.1007/s40744-018-0100-z)
Abstract ORCID
107.77 142
23 Evaluation of Usability and Acceptance of a New Autoinjector… (10.1007/s40744-017-0057-3)
Abstract ORCID License
107.35 26
24 Epigenetic Aspects of Systemic Lupus Erythematosus (10.1007/s40744-015-0014-y)
Abstract ORCID License
106.12 25
25 Clinical Examination, Ultrasound and MRI Imaging of The Pain… (10.1007/s40744-017-0053-7)
Abstract ORCID License
106.12 25
26 Assessing Methotrexate Adherence in Rheumatoid Arthritis: A… (10.1007/s40744-015-0011-1)
Abstract ORCID License
103.52 23
27 Usability and Patient Preference Phase 3 Study of the Sarilu… (10.1007/s40744-017-0090-2)
Abstract ORCID License
103.52 23
28 A Review of Recent Advances Using Tocilizumab in the Treatme… (10.1007/s40744-018-0102-x)
Abstract ORCID
102.46 111
29 Long-Term Safety and Efficacy of Subcutaneously Administered… (10.1007/s40744-016-0043-1)
Abstract ORCID License
102.13 22
30 Understanding and Minimising Injection-Site Pain Following S… (10.1007/s40744-020-00245-0)
Abstract ORCID
101.87 108
31 Efficacy and Safety of Secukinumab 150 mg with and Without L… (10.1007/s40744-018-0123-5)
Abstract ORCID
101.06 104
32 Comparison of Biologic Disease-Modifying Antirheumatic Drug… (10.1007/s40744-014-0006-3)
Abstract ORCID License
100.68 21
33 Comparative Efficacy of Bisphosphonates to Prevent Fracture… (10.1007/s40744-016-0030-6)
Abstract ORCID License
100.68 21
34 Collagenase Treatment in Dupuytren Contractures: A Review of… (10.1007/s40744-016-0027-1)
Abstract ORCID License
99.17 20
35 Impact of Participation in the Adalimumab (Humira) Patient S… (10.1007/s40744-017-0061-7)
Abstract ORCID License
99.17 20
36 Perceptions and Preferences of Two Etanercept Autoinjectors… (10.1007/s40744-016-0035-1)
Abstract ORCID License
97.58 19
37 Predictors of Atherosclerosis in Ankylosing Spondylitis (10.1007/s40744-015-0017-8)
Abstract ORCID License
95.91 18
38 Topical Diclofenac, an Efficacious Treatment for Osteoarthri… (10.1007/s40744-020-00196-6)
Abstract ORCID
95.69 81
39 Autoimmunity and Inflammation Link to Cardiovascular Disease… (10.1007/s40744-019-00189-0)
Abstract ORCID
95.42 80
40 Risk Associated with Cumulative Oral Glucocorticoid Use in P… (10.1007/s40744-018-0112-8)
Abstract ORCID
94.60 77
41 Efficacy and Safety of Subcutaneous Secukinumab 150 mg with… (10.1007/s40744-019-0163-5)
Abstract ORCID
94.60 77
42 Network Meta-Analysis and Cost Per Responder of Tumor Necros… (10.1007/s40744-016-0038-y)
Abstract ORCID License
94.15 17
43 A Retrospective Analysis of Corticosteroid Utilization Befor… (10.1007/s40744-017-0089-8)
Abstract ORCID License
94.15 17
44 Patient Perceptions of Unmet Medical Need in Rheumatoid Arth… (10.1007/s40744-019-00168-5)
Abstract ORCID
93.46 73
45 Renal Disease in Primary Sjögren’s Syndrome (10.1007/s40744-020-00264-x)
Abstract ORCID
92.87 71
46 Biologics Prescribing for Rheumatoid Arthritis in Older Pati… (10.1007/s40744-015-0021-z)
Abstract ORCID License
92.28 16
47 Worldwide, 3-Year, Post-Marketing Surveillance Experience wi… (10.1007/s40744-018-0097-3)
Abstract ORCID
91.94 68
48 Malignancy Incidence, Management, and Prevention in Patients… (10.1007/s40744-017-0064-4)
Abstract ORCID
91.30 66
49 Spebrutinib (CC-292) Affects Markers of B Cell Activation, C… (10.1007/s40744-019-00182-7)
Abstract ORCID
89.97 62
50 Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers… (10.1007/s40744-021-00288-x)
Abstract ORCID
88.91 59